Laboratorio de Neurofisiología del Control y la Regulación, Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Calz México-Xochimilco 101, Colonia Huipulco, Alcaldía Tlalpan, C.P. 14370, Ciudad de México, Mexico. Electronic address: davmv2@gmail.com.
2 papers in the library · 43 citations · publishing 2022-2024
High doses of Psilocybe cubensis mushroom, given orally or by injection, produced antidepressant- and anxiety-reducing effects in mice without signs of neurotoxicity. The mushroom's polar aqueous extract, which contained psilocybin and psilocin, was particularly effective. In behavioral tests, the mushroom and its extracts matched the effects of standard antidepressant and anti-anxiety drugs. The lethal dose was greater than 2000 mg/kg, indicating low acute toxicity. These preclinical results suggest the mushroom may be a safe and effective treatment for anxiety and depression.
A hydroalcoholic extract of Tabernaemontana arborea and its alkaloids ibogaine and voacangine altered brain electrical activity in mice. The extract at 56.2 and 100 mg/kg and ibogaine at 30 mg/kg increased delta and reduced alpha EEG band power, indicating central nervous system depression. Voacangine at 30 mg/kg flattened EEG patterns. None of the treatments modified seizures induced by pentylenetetrazole, but the extract at 100 mg/kg combined with the convulsant caused sudden death. Paroxysmal EEG activity from the extract and ibogaine was explored; a serotonin 5-HT1A receptor antagonist blocked the extract's but not ibogaine's paroxysmal activity, implicating serotonin neurotransmission in the extract's excitatory effects.